Fig. 2

On univariate analysis, the 1-year local control (LC) rates for stereotactic radiosurgery (SRS) with concurrent targeted/ immunotherapy (TT/IT) and SRS alone were 100 and 83.3% (p = 0.023) (a). Melanoma-molGPA as another prognostic factor was also associated with improved LC (p < 0.001) (b)